VBI Vaccines, Inc. (NASDAQ:VBIV) major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were acquired at an average cost of $3.05 per share, with a total value of $2,000,000.90. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/02/vbi-vaccines-inc-vbiv-major-shareholder-opko-health-inc-buys-655738-shares-of-stock.html.

Several research analysts have recently commented on VBIV shares. ValuEngine lowered VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Noble Financial reissued a “buy” rating on shares of VBI Vaccines in a report on Monday, July 31st. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th. Finally, Canaccord Genuity started coverage on VBI Vaccines in a report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

A number of institutional investors and hedge funds have recently modified their holdings of VBIV. Northern Trust Corp bought a new stake in VBI Vaccines during the 2nd quarter valued at approximately $883,000. State Street Corp bought a new stake in VBI Vaccines during the 2nd quarter valued at approximately $831,000. KCG Holdings Inc. bought a new stake in VBI Vaccines during the 1st quarter valued at approximately $512,000. Goldman Sachs Group Inc. bought a new stake in VBI Vaccines during the 1st quarter valued at approximately $383,000. Finally, TIAA CREF Investment Management LLC bought a new stake in VBI Vaccines during the 2nd quarter valued at approximately $262,000. 31.50% of the stock is currently owned by institutional investors.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Stock Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related stocks with our FREE daily email newsletter.